Expression of CKS2 in Hepatocellular Carcinoma: Correlation with Survival Outcomes and Immune Microenvironment

References

• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450–1462. doi:10.1056/NEJMra1713263
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Seong J. Challenge and hope in radiotherapy of hepatocellular carcinoma. Yonsei Med J. 2009;50(5):601–612. doi:10.3349/ymj.2009.50.5.601
   PubMed Web of Science ®Google Scholar
• Zheng Z, Liang W, Wang D, et al. Adjuvant chemotherapy for patients with primary hepatocellular carcinoma: a meta-analysis. Int J Cancer. 2015;136(6):E751–E759. doi:10.1002/ijc.29203
   PubMed Web of Science ®Google Scholar
• Marin J, Cives-Losada C, Asensio M, Lozano E, Briz O, Macias R. Mechanisms of anticancer drug resistance in hepatoblastoma. Cancers. 2019;11(3):407. doi:10.3390/cancers11030407
   PubMed Web of Science ®Google Scholar
• Cerrito L, Ponziani FR, Garcovich M, et al. Regorafenib: a promising treatment for hepatocellular carcinoma. Expert Opin Pharmacother. 2018;19(17):1941–1948. doi:10.1080/14656566.2018.1534956
   PubMed Web of Science ®Google Scholar
• Ikeda M, Kobayashi M, Tahara M, Kaneko S. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib. Expert Opin Drug Saf. 2018;17(11):1095–1105. doi:10.1080/14740338.2018.1530212
   PubMed Web of Science ®Google Scholar
• Killock D. Nivolumab keeps HCC in check and opens avenues for checkmate. Nat Rev Clin Oncol. 2017;14(7):392. doi:10.1038/nrclinonc.2017.70
   PubMed Web of Science ®Google Scholar
• Shi Y, Men X, Li X, Yang Z, Wen H. Research progress and clinical prospect of immunocytotherapy for the treatment of hepatocellular carcinoma. Int Immunopharmacol. 2020;82:106351. doi:10.1016/j.intimp.2020.106351
   PubMed Web of Science ®Google Scholar
• Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2021;19(3):151–172. doi:10.1038/s41571-021-00573-2
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–1355. doi:10.1126/science.aar4060
   PubMed Web of Science ®Google Scholar
• Pines J. Cell cycle: reaching for a role for the Cks proteins. Curr Biol. 1996;6(11):1399–1402. doi:10.1016/S0960-9822(96)00741-5
   PubMed Web of Science ®Google Scholar
• Reynard GJ, Reynolds W, Verma R, Deshaies RJ. Cks1 is required for G(1) cyclin-cyclin-dependent kinase activity in budding yeast. Mol Cell Biol. 2000;20(16):5858–5864. doi:10.1128/MCB.20.16.5858-5864.2000
   PubMed Web of Science ®Google Scholar
• Yu M, Zhong M, Qiao Z. Expression and clinical significance of cyclin kinase subunit 2 in colorectal cancer. Oncol Lett. 2013;6(3):777–780. doi:10.3892/ol.2013.1456
   PubMed Web of Science ®Google Scholar
• Wang J, Xu L, Liu Y, et al. Expression of cyclin kinase subunit 2 in human breast cancer and its prognostic significance. Int J Clin Exp Pathol. 2014;7(12):8593–8601.
   PubMed Web of Science ®Google Scholar
• Shen D-Y, Zhan Y-H, Wang Q-M, Rui G, Zhang Z-M. Oncogenic potential of cyclin kinase subunit-2 in cholangiocarcinoma. Liver Int. 2013;33(1):137–148. doi:10.1111/liv.12014
   PubMed Web of Science ®Google Scholar
• Yang Z, Cheng H, Zhang Y, Zhou Y. Identification of NDRG family member 4 (NDRG4) and CDC28 protein kinase regulatory subunit 2 (CKS2) as key prognostic genes in adrenocortical carcinoma by transcriptomic analysis. Med Sci Monit. 2021;2021:27.
   Google Scholar
• Wang Z, Zhang M, Wu Y, Yu Y, Zheng Q, Li J. CKS2 overexpression correlates with prognosis and immune cell infiltration in lung adenocarcinoma: a comprehensive study based on bioinformatics and experiments. J Cancer. 2021;12(23):6964–6978. doi:10.7150/jca.63625
   PubMed Web of Science ®Google Scholar
• Ji X, Xue Y, Wu Y, Feng F, Gao X. High-expressed CKS2 is associated with hepatocellular carcinoma cell proliferation through down-regulating PTEN. Pathol Res Pract. 2018;214(3):436–441. doi:10.1016/j.prp.2017.12.006
   PubMed Web of Science ®Google Scholar
• Shen D-Y, Fang Z-X, You P, et al. Clinical significance and expression of cyclin kinase subunits 1 and 2 in hepatocellular carcinoma. Liver Int. 2010;30(1):119–125. doi:10.1111/j.1478-3231.2009.02106.x
   PubMed Web of Science ®Google Scholar
• Hu M, Li Z, Qiu J, et al. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry. Bioengineered. 2021;12(1):5996–6009. doi:10.1080/21655979.2021.1972197
   PubMed Web of Science ®Google Scholar
• Lian Q, Wang S, Zhang G, et al. HCCDB: a database of hepatocellular carcinoma expression atlas. Genomics Proteomics Bioinformatics. 2018;16(4):269–275. doi:10.1016/j.gpb.2018.07.003
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.002
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. doi:10.1093/nar/gkx247
   PubMed Web of Science ®Google Scholar
• Li Y, Ge D, Lu C. The SMART App: an interactive web application for comprehensive DNA methylation analysis and visualization. Epigenetics Chromatin. 2019;12(1):71. doi:10.1186/s13072-019-0316-3
   PubMed Web of Science ®Google Scholar
• Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956–D963. doi:10.1093/nar/gkx1090
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Zhang Q, He Y, Luo N, et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell. 2019;179(4):829–845.e820. doi:10.1016/j.cell.2019.10.003
   PubMed Web of Science ®Google Scholar
• Xu L, Deng C, Pang B, et al. TIP: a web server for resolving tumor immunophenotype profiling. Cancer Res. 2018;78(23):6575–6580. doi:10.1158/0008-5472.CAN-18-0689
   PubMed Web of Science ®Google Scholar
• Kulis M, Esteller M. DNA methylation and cancer. Adv Genet. 2010;70:27–56.
   PubMed Web of Science ®Google Scholar
• Paredes J, Albergaria A, Oliveira JOT, Jerónimo C, Milanezi F, Schmitt FC. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res. 2005;11(16):5869–5877. doi:10.1158/1078-0432.CCR-05-0059
   PubMed Web of Science ®Google Scholar
• Chen C-Y, J-J W, Lin Y-J, et al. Significance of hypermethylation of tumor-suppressor genes PTGER4 and ZNF43 at CpG sites in the prognosis of colorectal cancer. Int J Mol Sci. 2022;23:18.
   Web of Science ®Google Scholar
• Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525–543. doi:10.1038/s41575-021-00438-0
   PubMed Web of Science ®Google Scholar
• Forner A, Bruix J. Biomarkers for early diagnosis of hepatocellular carcinoma. Lancet Oncol. 2012;13:750–751. doi:10.1016/S1470-2045(12)70271-1
   PubMed Web of Science ®Google Scholar
• Chi G, Pei J, Li X, et al. SMYD5 acts as a potential biomarker for hepatocellular carcinoma. Exp Cell Res. 2022;414(2):113076. doi:10.1016/j.yexcr.2022.113076
   PubMed Web of Science ®Google Scholar
• Zhang Y, Pang S, Sun B, et al. ELOVLs predict distinct prognosis value and immunotherapy efficacy in patients with hepatocellular carcinoma. Front Oncol. 2022;2022:12.
   Google Scholar
• Fernández-Palanca P, Payo-Serafín T, Fondevila F, et al. Neuropilin-1 as a potential biomarker of prognosis and invasive-related parameters in liver and colorectal cancer: a systematic review and meta-analysis of human studies. Cancers. 2022;14(14):3455. doi:10.3390/cancers14143455
   PubMed Web of Science ®Google Scholar
• Fondevila F, Fernández-Palanca P, Méndez-Blanco C, et al. Association of FOXO3 expression with tumor pathogenesis, prognosis and clinicopathological features in hepatocellular carcinoma: a systematic review with meta-analysis. Cancers. 2021;13(21):5349. doi:10.3390/cancers13215349
   PubMed Web of Science ®Google Scholar
• Tang Y, Guo C, Yang Z, Wang Y, Zhang Y, Wang D. Identification of a tumor immunological phenotype-related gene signature for predicting prognosis, immunotherapy efficacy, and drug candidates in hepatocellular carcinoma. Front Immunol. 2022;2022:13.
   Google Scholar
• Xu JH, Wang Y, Xu D. CKS2 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in epithelial ovarian cancer. Eur Rev Med Pharmacol Sci. 2019;23:3225–3234. doi:10.26355/eurrev_201904_17681
   PubMed Web of Science ®Google Scholar
• Yeung OWH, C-M L, Ling -C-C, et al. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. J Hepatol. 2015;62(3):607–616. doi:10.1016/j.jhep.2014.10.029
   PubMed Web of Science ®Google Scholar
• Wirtz TH, Brandt EF, Berres M-L. Liver DCs in health and disease. Int Rev Cell Mol Biol. 2019;348:263–299.
   PubMed Web of Science ®Google Scholar
• Luo G, Xu J, Xia Z, et al. SSRP1 is a prognostic biomarker correlated with CD8+ T cell infiltration in hepatocellular carcinoma (HCC). Biomed Res Int. 2021;2021:1–10. doi:10.1155/2021/4014797
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–262. doi:10.1016/j.celrep.2016.12.019
   PubMed Web of Science ®Google Scholar
• Ehling J, Tacke F. Role of chemokine pathways in hepatobiliary cancer. Cancer Lett. 2016;379(2):173–183. doi:10.1016/j.canlet.2015.06.017
   PubMed Web of Science ®Google Scholar
• Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572. doi:10.1038/nri.2017.49
   PubMed Web of Science ®Google Scholar
• Lin T, Zhang E, Mai -P-P, Zhang Y-Z, Chen X, Peng L-S. CXCL2/10/12/14 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma. Biosci Rep. 2021;41(6). doi:10.1042/BSR20204312
   Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi:10.1016/j.immuni.2013.07.012
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Nie X, Desai SS, et al. A Burned-Out CD8+ T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy. Cancer Discov. 2021;11(7):1700–1715. doi:10.1158/2159-8290.CD-20-0962
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807–821. doi:10.1038/s41423-020-0488-6
   PubMed Web of Science ®Google Scholar